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Wound healing is an area of unmet clinical need. Current treatments include occlusive dressings, hydrogels, and antimicrobials
to control infection. However with the growing number of antibiotic-resistant bacteria and the increase in population age and
clinical obesity, it is becoming proportionally harder to treat wounds with the drugs that have worked in the past. There is an
urgent requirement for efficient mechanism-based treatments and more efficacious drug delivery systems. The potential of using
nanoparticles as a drug delivery system has been identified and investigated. Nanoparticles have the ability to protect and carry
drugs to specific targets in the body, enabling slower degradation, enhancing drug penetration, improving treatment efficacy with
lower systemic absorption, and reducing unwanted side effects. Here we discuss the advantages and limitations of nanotechnology
for the treatment of wounds and other cutaneous disorders.
1. Introduction
The skin is the largest organ in the body and is the first line
of defence against invading pathogens.The primary function
of the skin is to act as a protective barrier against the envi-
ronment as any large insult or loss of skin integrity can lead to
disability or death [1, 2]. Adult cutaneous wound healing is a
complicated process involving a cascade of events and inter-
actions between numerous cells and cellmediators [3, 4].This
process aims to restore the complete skin barrier function
quickly, often at the expense of correct anatomical repair [5].
There are several dressings and devices currently available on
the medical wound care market impregnated with a range of
compounds which aim to optimise the wound healing envir-
onment, providing faster, more efficient wound healing [6].
There are, however, many limitations with using these dress-
ings in clinical practice including poor skin penetration, low
stability, and localised side effects. Consequently, there is a
need for the development of novel and more efficient drug-
delivery systems [7]. The advent of nanotechnologies has the
potential to fulfil this and the design and implementation of
target-selective, time-controlled drug delivery systems for
cutaneous healing and regenerative medicine now exists
[8, 9].
While naturally occurring nanoporous minerals have
been used on an industrial scale as effective catalysts for dec-
ades, today there are a number of different substances used
for the production of nanoporousmaterials including carbon,
silicon, silicates, ceramics, metals, various polymers, metallic
minerals, and compounds of organic materials [10]. The use
of micro- and nanotechnology is becoming more frequent in
biomedical science, both in the development of diagnostics
and in clinical therapies. Development of novel therapies in
cutaneous healing has been greatly facilitated by the discov-
ery of novel nanomaterials including nanoparticles, nanotu-
bes, nanoengineered scaffolds, and nanoscale surface modi-
fications [11]. The use of this technology has the potential
to increase drug efficacy and decrease adverse effects by deliv-
ering specific quantities of drugs to specific target sites over
a determined period of time. Nanomaterials are currently
being investigated for their applications in cutaneous wound
healing and their potential uses include molecule delivery,
nanofibres for tissue scaffolds and surface modification for
implantable materials [12]. Nanotherapy is manipulation of
matter, at an atomic or molecular scale, used for delivery of
therapeutic agents to tissues in vivo [13]. The main exam-
ples of nanotherapy being developed for use in cutane-
ous medicine include solid lipid nanoparticles, which are
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nanoparticles made of lipids and lipids blends, and nanos-
tructured lipid carriers, a second generation of smarter drug
carrier systems made up of physiological, biodegradable, and
biocompatible lipid materials and surfactants.These are both
currently accepted as applicable routes for the delivery of
drugs in vivo [14, 15]. The aim of this paper is to review
the potential of nanomaterials for the improvement of cuta-
neous healing, while comparing current clinical therapies to
developing ones and assessing the strengths and limitations
of both.
2. Transcutaneous Delivery of Nanoparticles
Penetration of nanoparticles through intact skin is a contro-
versial topic and has been a major focus of research in both
the pharmaceutical and cosmetic industry examining the
transcutaneous delivery of both nonbiodegradable and bio-
degradable nanomaterials [16]. Titanium dioxide (TiO2) and
zinc oxide (ZnO) are two of the most widely characterized
nonbiodegradable nanoparticles studied in this regard due to
their wide use in both sunscreens and cosmetics. There are,
however, conflicting studies reporting on the epidermal pen-
etration of titanium dioxide and its accumulation in several
majors organs. This has raised safety and toxicity concerns
due to oxidative stress induced by deposited nanoparticles
after prolonged dermal exposure [13, 17]. In recent years,
however, developments in nanotechnology have highlighted
the potential use of biodegradable nanoparticles including
liposomes, niosomes, nanosized emulsions, and solid lipid
nanoparticles as the carrier systems for drug delivery through
the protective stratum corneum [18]. Solid lipid nanoparticles
(SLN) are a new generation of nanoparticulate active-sub-
stance vehicles with advantages of controlled release, low irri-
tation, and protection of active compounds [19]. Their small
particle size ensures close contact with the stratum corneum
and improved penetration of the encapsulated agent through
the skin layers [20]. The complete biodegradation of lipid
nanoparticles and their biocompatible chemical nature has
highlighted lipid nanoparticles as “nanosafe carriers” for top-
ical drug delivery with studies examining their use for deliv-
ery of glucocorticoids (prednicarbate, betamethasone, and
prednisolone) and nonsteroidal anti-inflammatory drugs (in-
domethacin, celecoxib, ketoprofen, ketorolac, flurbiprofen)
for potential treatment of acne, skinmycoses, atopic dermati-
tis, and psoriasis [21].
The efficacy of topically applied drugs used in clinical der-
matology is determined by their mechanism of action and
their ability to pass through the protective skin barrier. Drug
permeation through the skin occurs via the passive diffusion
of drugs through the transepidermal or transappendageal
route [13]. In contrast, transcutaneous delivery of nanoparti-
cles is dependent on a number of factors including desquama-
tion rate of stratum corneum, permeation pathway, and the
size of nanoparticles [22].Themajority of studies to date sug-
gest that nanoparticles only permeate the superficial layers of
the skin in vivo and remain in the stratum corneum, while
only a few studies suggest full epidermal penetration and
dermal absorption. It is generally accepted that nanoparticles
do not diffuse across the basement membrane and their dep-
osition in the skin occurs through follicular penetration
(Figure 1(a)) [18]. In the context of clinical dermatology, con-
trolled drug delivery and release via the hair follicles using
nanoparticles offer an exciting opportunity for therapy devel-
opment as hair follicles are surrounded by capillaries and
antigen presenting cells, are associated with the sebaceous
glands, and are the host of stem cells in the bulge region of the
hair follicle [23]. Consequently delivery of drugs, proteins,
or antibodies to the epidermis through follicular penetration
offers novel avenues of therapy development for number of
dermatological conditions where patients still have intact
skin eg eczema, psoriasis, mycoses and atopic dermatitis (fur-
ther discussed in Section 4 and Table 1).
One area of current research focus is the potential use of
nanoparticles for noninvasive transcutaneous immunisation.
Compared to microparticles which cannot penetrate the skin
to the extent that would allow the application of the required
dose of antigen nanoparticles, delivery through the follicular
pathway has been shown to penetrate deeper into the hair
follicle than molecules in solution, help stabilize the protein
based antigens, and can improve and modulate immune res-
ponse [40]. This particular route of drug/vaccine delivery is
particularly important for immunocompromised patients
including the elderly, patients with poor wound healing, and
young children [41]. Studies by Mittal et al. demonstrate an
effective needle-free application of vaccines across the skin by
delivery of polymeric nanoparticles using ovalbumin antigen
and a double emulsion nanotechnology method using phar-
maceutically biocompatible and biodegradable polymers
poly(lactide-co-glycolide) (PLGA) or chitosan-coated PLGA
(Chit-PLGA) demonstrating increased protection from
cleavage and functional biological activity of the antigen [41].
In addition, epidermal permeation of nanoparticles has also
been reported following mechanical stress including the use
of harsh vehicles or skin damage following needle puncture
or wounding [13].
Transcutaneous delivery of nanoparticles and dermal ab-
sorption of drugs, proteins, or antibodies to patients suffering
from chronic inflamed wounds or nonhealing ulcers are not
hindered by the protective skin barrier as those patients have
large open wounds. For patients with open wounds, treat-
ments can be delivered using nanotechnology by incorporat-
ing drug carrying nanoparticles into dressings or hydrogels
allowing controlled sustained release of nanoparticles to the
dermis (Figure 1(b)). Preliminary in vitro and in vivo studies
have shown that both solid lipid nanoparticle and nanos-
tructured lipid carrier hydrogels can be used to successfully
deliver flurbiprofen to skin with sustainable and controlled
drug delivery over 24 hrs with functional anti-inflammatory
effects on the tissue [30]. Current research developments are
focused on designing biodegradable dressings and dermal
scaffolds incorporating nanoparticle delivery systems for the
controlled release of drugs, proteins, and antibodies to open
wounds in vivo.
The use of antibody based therapy for treatment of cuta-
neous diseases has been demonstrated previously with
Infliximab (trade name Remicade), a monoclonal antibody
against tumour necrosis factor alpha (TNF-𝛼) used to treat
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Figure 1:Nanoparticle technology for transcutaneous delivery of drug agents to intact orwounded skin leading to improvedwoundoutcomes.
(a) Transepithelial delivery of nanoparticles is limited by the poor penetration through the protective stratum corneum. Transappendageal
nanoparticle delivery through hair follicle offers potential for treatment of conditions where skin is intact. ((b)-(c)) Incorporation of drug
carrying nanoparticles into dressings and scaffolds allows controlled sustained release of biologically active agents into open wounds
intradermally hence resulting in improved healing and reduced scarring.
Table 1: The use of nanoparticle technology for delivery of drugs transcutaneously targeting the most common cutaneous pathologies.
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autoimmune diseases including psoriasis [42]. While the use
of nanotechnology for the delivery of antibodies to wounds
using scaffolds in vivo is yet to be demonstrated, nanotech-
nology has been used in numerous studies exploring the
delivery of antibodies to tissue in vivo using experimental
animals models of breast [43] and colon [44] cancer and
osteoarthritis [45]. In addition, recent studies using nano-
medicine to deliver therapeutic antibody in the experimental
model of myeloma have shown that a combination therapy of
anti-ABCG2mAb and paclitaxel loaded iron oxide magnetic
nanoparticles has a significant effect on reduction of tumour
growth in vivo compared to paclitaxel, iron oxide nanoparti-
cles, or anti-ABCG2mAb treatment alone hence demonstrat-
ing the synergetic effect of combinational therapy in nano-
medicine [46].
3. Nanotechnology and Cutaneous Infection
With the evolution of new antibiotic resistant strains of bacte-
ria, wound infection rates are increasing andmore aggressive
wound management is required [47]. Infection in wounds,
particularly in chronic, nonhealing, and burn wounds is a
leading cause of morbidity andmortality. Good clinical prac-
tice involves using systemic and topical antimicrobial pro-
phylaxis to reduce themicrobial load in thewound as infected
wounds have slower healing outcomes [48]. One of the cur-
rent strategies for combating these infections is the use of
noblemetals as antimicrobial agents.The leader in this field is
silver which has been used for its antimicrobial properties for
centuries [49]. Silver based compounds are highly toxic to
microorganisms showing strong effects on 16 bacterial species
including E. coli [50]. It is now regularly used as an antimi-
crobial prophylaxis treatment for burns, open wounds, and
chronic ulcers [51]. Silver in its metallic state is inert but upon
reaction with wound fluid andmoisture from skin it becomes
ionized and highly reactive [52]. It binds to tissue proteins,
blocks bacterial respiratory enzyme pathways, and causes
structural changes of the bacterial cell wall and nuclearmem-
brane hence leading to cell death [53–55].Nanosilver particles
are commonly used in many forms in the treatment of
wounds. Silver nitrate is a common antimicrobial used in the
treatment of chronic wounds; however, it can be irritating to
tissues and also causes semipermanent staining of tissues and
surfaces to which it contacts [56]. Silver sulfadiazine (SSD)
was introduced as a topical chronic and burn wound treat-
ment in the 1960s to overcome the shortcomings of silver
nitrate, but both are limited due to a short therapeutic win-
dow, silver inactivation bywoundfluid, and the formation of a
pseudoeschar [57]. Using new nanotechnology to create sus-
tained release of silver nanoparticles increases the therapeutic
window of each dressing. One of these nanosilver impreg-
nated dressings is Acticoat, which is an absorbent rayon-pol-
yester core sandwiched between two layers of silver-coated,
high-density polyethylene [57].The outer layer works to pro-
vide antimicrobial effects whilst the inner core maintains a
moist wound environment [58].
The use of silver dressings for the management of burns
and chronic wounds is now a globally accepted therapy, with
Acticoat leading the way for the worldwide management of
burns. The efficacy of Acticoat and silver sulfadiazine against
several strains of bacteria including MRSA showed 100%
clearance for both dressings by the end of the study. Acticoat;
however, showed a significantly higher clearance at days 6 and
12 [59]. The effectiveness of Acticoat to chlorhexidine acetate
and fusidic acid also showed no significant difference in
effectiveness against resistant bacteria, however Acticoat was
suggested as the best choice of treatment due to its sustained
release properties [60].
New advances in polymer technology are allowing many
dressings, previously used only to provide an optimal healing
environment, to be impregnated with silver nanoparticles to
add to their effectiveness. Bacterial cellulose hydrogels pro-
duced byAcetobacter xylinum have long been used to provide
an effective, moist healing environment but without any anti-
microbial activity, and the risk of infection was high. Impreg-
nation of these dressings with silver nanoparticles by immer-
sion in silver nitrate has significantly improved the efficiency
of these hydrogels [61]. Although the powerful antimicrobial
effects of silver compounds are well documented, there is evi-
dence to suggest that it may have a negative effect on wound
healing. Studies have shown that silver compounds can delay
wound healing by extending the inflammation phase [62].
They have also been shown to be highly toxic to keratinocytes
and fibroblasts [51]. A large oral intake of silver causes a con-
dition known as “argyria” which is characterised by silver
granule deposition into the skin leading to a permanent blue/
gray discoloration [63]. In patients affected by argyria, silver
granules can be found in all organs of the body and recent case
studies have suggested that argyria can be an effect of topical
delivery of silver in dressings such as Acticoat [64–66].
Treatment of burn wounds with Acticoat has caused raised
liver enzymes and argyria like symptoms in some patients
[67]. This has resulted in changes in clinical guidelines with
current recommendation of using these dressings for shorter
period of time and intermittently hence highlighting the need
for improved design of dressings with antibacterial activity
and functional wound promoting ability.
4. Dermatological Advances
Skin diseases are one of themost widespread complaints with
over 80% of the population suffering from a condition at
some point in their lives [68]. Although some are merely a
cosmetic issue, others are more serious, causing pain, severe
scarring, andmorbidity. Due to the lower risk of systemic side
effects and the ability to apply directly to the problem area,
topical treatments of skin disease are preferred [69]. Current
treatments are effective but many carry severe side effects so
there remains a need for more advanced technology and
nanotechnology is fast becoming a leader in this field.
Acne is a common skin disease with a high rate of pre-
valence in adolescents. It is characterised by increased sebum
production, ductal cornification, bacterial colonization of the
pilosebaceous ducts, and inflammation [70]. Acne can be
severe and often results in permanent scarring and disfigure-
ment. The most common treatment for mild to moderate
Journal of Nanomaterials 5
acne is the use of oral retinoids.This is a highly effective treat-
ment option; however, it does cause a high incidence of side
effects including sensitivity to sunlight, irritation, and ery-
thema, resulting in low patient compliance. The encapsula-
tion of retinoids into solid lipid nanoparticles (SLN) for use
as a topical treatment has increased drug penetration, im-
proved efficacy, and reduced side effects [61]. The current
treatment formoderate to severe and prolonged acne involves
the use of oral antiandrogens, such as combined cyproterone
acetate/ethinyl estradiol to reduce sebum secretion and acne
lesions. However, these drugs have severe side effects includ-
ing feminisation of themale fetus in females, and use inmales
can lead to loss of libido, gynecomastia, and loss of bonemin-
eral density [71]. To avoid these systemic effects and to reduce
the side effects, research has led to the discovery of liposomes
and solid lipid nanoparticles (SLN) loaded with steroidal and
antisteroidal antiandrogens (drospirenone and cyproterone).
The use of these nanoparticles increases drug penetration
fourfold, increases the efficacy, and reduces the side effects
when compared to oral drug options [72].
Psoriasis is a chronic skin inflammatory disorder that
drastically impairs quality of life.Themost common forms of
treatment currently are topical; however, with limited infor-
mation on their mechanism of action and evidence of accu-
mulation in adipose tissue [73], their use in clinical practice
is limited.The advent of new lipid nanoparticle drug delivery
systems has the possibility to improve the efficacy and safety
of these topical compounds [68]. One of the most common
treatments for mild psoriasis is topical application of Tret-
inoin, a metabolite of vitamin A. Although effective against
psoriasis, this treatment has severe side effects including ery-
thema, burning, and increased sensitivity to light [74]. To
overcome this, tretinoin has been incorporated into SLN,
which not only improved permeation and efficacy, but also
significantly decreased the incidence of erythema and sun
sensitivity [75]. More severe psoriasis can be treated with
Acitretin, an oral retinoid which although effective also has
severe side effects including alopecia, skin peeling, and chei-
litis [76]. Once incorporated into SLN, a higher deposit of
Acitretin at the plaque site as well as significantly improved
therapeutic response and a significant reduction in local side
effects has been observed [68]. In addition, a recent clinical
trial using Acitretin delivered via nanostructured lipid car-
riers demonstrated significantly improved clinical effects on
patients with psoriasis [15].
Fungal skin infections are one of themost widespread dis-
eases known to man with topical therapy the preferred
method of treatment due to high patient compliance, self-
administration, and low risk of systemic side effects [77]. Cur-
rent treatments although effective are relatively slow-acting
and so SLN are being investigated to improve efficacy. There
are several antifungal agents used for the treatment of human
mycoses which are currently undergoing investigation of
their efficacywhen incorporatedwith SLN includingmicona-
zole nitrate [78], clotrimazole [79], ketoconazole [80] and
econazole nitrate [35].
The results from these studies show that when the drugs
were incorporated into an SLN there was an increased rate
and level of skin penetration, higher efficacy, and less local
side effects. Selected examples of current research develop-
ments using nanoparticle technologies for the delivery of
drugs transcutaneously are presented in Table 1.
5. Development of Nanoengineered
Dermal Scaffolds for Improved Healing
and Reduced Scar Formation
The impact of scarring, both mentally and physically, im-
mensely affects a large number of patients and their families
which is often witnessed following burn injuries to large area
of the body. Currently, there is a lack of effective scaffold treat-
ments available for treatments of nonhealingwounds, with no
approved scaffold treatments that have been shown to reduce
scar formation during wound healing [81]. In the case of
major burns where injury damages the deep dermis and no
sources of cells for regeneration remain, there is a require-
ment to provide a dermal scaffold to fill in the deep wound
[82]. Current commercial products address some of the
immediate demands of wound care including protective cov-
ering or lost epidermal/dermal material; however, these are
far from optimal, often addressing only one aspect of injury.
Current scaffolds are made from xenobiotic animal derived
materials and have short shelf life, nontrivial application, and
high production costs [81, 83]. While there is a wide range
of biologic and polymeric materials currently available on
the market their efficacy is far from optimal highlighting the
need for the development of next generation scaffolds which
actively promote healing, and decrease scarring [81].
In the past five years there has been a significant increase
in the in vivo use of both synthetic and natural biodegradable
polymers and materials. Through the process of electrospin-
ning, nanofibres can be processed to create nanofibrous scaf-
folds with open and interconnected porosity. Poly-(𝜀-capro-
lactone) (PCL)/gelatin nanofibrous scaffolds have been
shown to have improved biocompatibility and improved
mechanical, physical, and chemical properties, allowing im-
proved wound healing and dermal reconstitution [82]. In
addition, nanofibrous scaffolds facilitate the impregnation of
allogeneic keratinocytes, xenogenic fibroblasts, and antibac-
terial agents for improved wound healing and decreased
infection rates [14, 84, 85].
Theuse of nanotechnology nowprovides a novel platform
for the design of functionalized, treatment specific scaffolds
which, in addition to providing a matrix for cell proliferation
and differentiation, can also carry drug containing nanopar-
ticles. Enzymes, present in the wound environment, can dy-
namically degrade the nanoparticles allowing the optimal
dose of biologically active drug to be released intradermally
over a sustained period. This may promote rapid cellular
migration under the dressing and onto and into the scaffold,
resulting in regenerative wound healing and reduced scar
formation (Figure 1(c)). While the use of nanotechnology for
drug delivery using dermal scaffold is still being developed,
further research in nanomedicine offers hope for improved
treatment options in cutaneous medicine.
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6. Conclusion
Nanotechnology presents an exciting new opportunity for the
development of a safer and more efficient drug strategy for
many dermatological conditions.While there are a number of
examples of nanoparticle cosmetic products currently on the
market, commercially available nanoparticle products for
drug delivery through healthy orwounded skin are still under
development [21, 22]. With the advent of new nano-based
drug delivery systems which can be specifically formulated to
target specific cells and fit a desired release profile and pen-
etration depth, the face of medical research is truly evolving.
There is, however, much research still to be performed to
understand the chronic effects and to continue to improve
patient tolerance and drug efficacy in vivo.
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